Group 1 - The core viewpoint of the news is that Baiyang Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.02% and a current price of 24.72 yuan per share, resulting in a market capitalization of 12.993 billion yuan [1] - Baiyang Pharmaceutical's main business involves providing comprehensive commercialization solutions for pharmaceutical product manufacturers, including brand operation, wholesale distribution, and retail, with brand operation accounting for 72.41% of total revenue [1] - The company has seen a year-to-date stock price increase of 4.75%, with a 3.30% rise over the last five trading days and a 9.14% increase over the last 20 days, while experiencing a 6.89% decline over the last 60 days [1] Group 2 - As of September 30, the number of shareholders for Baiyang Pharmaceutical is 11,100, a decrease of 40.83% from the previous period, while the average circulating shares per person increased by 68.99% to 47,194 shares [2] - For the period from January to September 2025, Baiyang Pharmaceutical reported a revenue of 5.627 billion yuan, a year-on-year decrease of 8.41%, and a net profit attributable to shareholders of 476 million yuan, down 25.67% year-on-year [2] - Since its A-share listing, Baiyang Pharmaceutical has distributed a total of 1.551 billion yuan in dividends, with 1.201 billion yuan distributed over the past three years [3]
百洋医药跌2.02%，成交额2.00亿元，主力资金净流出835.58万元